• Baroyeca (BGS) has assayed up to 986.6 g/t AgEq at the Atocha Project in Tolima, Colombia
  • The results stem from three additional drill holes from the phase 2 program
  • Further drilling will target the northeast along strike to delineate a developing mineralized shoot
  • Raul Sanabria, President of Baroyeca, sat down with Sabrina Cuthbert to highlight the results
  • Baroyeca Gold & Silver operates high-grade silver and gold projects in Colombia
  • Baroyeca (BGS) is down by 2.78 per cent, trading at $0.175 per share

Baroyeca (BGS) has assayed up to 986.6 g/t AgEq at the Atocha Project in Tolima, Colombia.

The results stem from three additional drill holes from the phase 2 program.

Raul Sanabria, President of Baroyeca, sat down with Sabrina Cuthbert to highlight the results.

“We are on track in our phase 2 drill program at our flagship Atocha Project and starting to see similar results as at our previously drilled La Ye target, reaching almost one kilo per tonne silver equivalent. The new assay results continue to show the quality of this project in just the second zone tested. The next drill holes will continue to the northeast along strike where a mineralized shoot is starting to be developed while we try to connect this zone with La Ye and prove the first continuous 1 km plus vein corridor.”

Baroyeca Gold & Silver operates high-grade silver and gold projects in Colombia.

Baroyeca Gold & Silver Inc. (BGS) is down by 2.78 per cent trading at $0.175 per share at 12 pm ET.

More From The Market Online
The Market Online Video

Exploration company provides project portfolio update

Banyan Gold Corp. (TSXV:BYN) is focused on exploration and advancing and de-risking its AurMac Gold Project in the Yukon.
stock market down

@ the Bell: Industrials weakness snaps TSX win streak

Industrials led decliners, followed by financials, to snap the TSX’s five-day win streak while energy, utilities and mining provided gains.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.